Spero Therapeutics (SPRO) Total Current Liabilities (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Total Current Liabilities came in at $5.5 million in Q1 2026, down 81.17% YoY from $29.2 million in Q1 2025, and down 38.1% on a QoQ basis from $8.9 million in Q4 2025.
Spero Therapeutics (SPRO) Total Current Liabilities (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Total Current Liabilities data on file, last reported at $5.5 million in Q1 2026.
- Quarterly Total Current Liabilities fell 81.17% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (down 81.17% YoY) and the FY2025 annual result came in at $8.9 million, down 81.93% from the prior year.
- Total Current Liabilities retreated to $5.5 million in Q1 2026, from $8.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $69.2 million in Q1 2022 to a low of $5.5 million in Q1 2026.
- A 5-year average of $28.4 million and a median of $23.0 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 289.57% — and 2025, when it plunged 81.93%.
- Tracing SPRO's Total Current Liabilities over 5 years: stood at $21.6 million in 2022, then soared by 71.62% to $37.2 million in 2023, then surged by 32.09% to $49.1 million in 2024, then sank by 81.93% to $8.9 million in 2025, then plunged by 38.1% to $5.5 million in 2026.
- The last three Total Current Liabilities figures came in at $5.5 million (Q1 2026), $8.9 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 8.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.43 Mn |
| Mar 31, 2026 | 5.49 Mn |
| Dec 31, 2025 | 8.87 Mn |
| Sep 30, 2025 | 13.65 Mn |
| Jun 30, 2025 | 14.95 Mn |
| Mar 31, 2025 | 29.16 Mn |
| Dec 31, 2024 | 49.07 Mn |
| Sep 30, 2024 | 49.10 Mn |
| Jun 30, 2024 | 45.63 Mn |
| Mar 31, 2024 | 41.82 Mn |
| Dec 31, 2023 | 37.15 Mn |
| Sep 30, 2023 | 25.46 Mn |
| Jun 30, 2023 | 17.32 Mn |
| Mar 31, 2023 | 22.99 Mn |
| Dec 31, 2022 | 21.65 Mn |
| Sep 30, 2022 | 16.23 Mn |
| Jun 30, 2022 | 14.23 Mn |
| Mar 31, 2022 | 69.20 Mn |
| Dec 31, 2021 | 18.67 Mn |
| Sep 30, 2021 | 17.26 Mn |